Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea

References

• International Diabetes Federation. IDF diabetes ATLAS ninth edition; 2019. Available from: https://diabetesatlas.org/atlas/ninth-edition/. Accessed July 15, 2020.
   Google Scholar
• Kim JH, Kim DJ, Jang HC, Choi SH. Epidemiology of micro- and macrovascular complications of type 2 diabetes in Korea. Diabetes Metab J. 2011;35(6):571–577. doi:10.4093/dmj.2011.35.6.571
   Google Scholar
• Statistics Korea: 2009 statistical results about cause of death; 2011. Available from: http://www.index.go.kr. Accessed September 15, 2019.
   Google Scholar
• Lee WJ, Song KH, Noh JH, Choi YJ, Jo MW. Health-related quality of life using the EuroQol 5D questionnaire in Korean patients with type 2 diabetes. J Korean Med Sci. 2012;27(3):255–260. doi:10.3346/jkms.2012.27.3.255
   PubMed Web of Science ®Google Scholar
• Kim EJ, Yoon SJ, Jo MW, Kim HJ. Measuring the burden of chronic diseases in Korea in 2007. Public Health. 2013;127(9):806–813. doi:10.1016/j.puhe.2012.12.024
   Web of Science ®Google Scholar
• Korean Diabetes Association. Diabetes fact sheet in Korea; 2018. Available from: http://www.diabetes.or.kr/pro/news/admin.php?category=A&code=admin&number=1546&mode=view. Accessed September 15, 2019.
   Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2019 executive summary. Endocr Pract. 2019;25(1):69–100. doi:10.4158/CS-2018-0535
   PubMed Web of Science ®Google Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary. Endocr Pract. 2020;26(1):107–139. doi:10.4158/CS-2019-0472
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 6. Glycemic targets: standards of Medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S55–S64. doi:10.2337/dc18-S006
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S66–S76. doi:10.2337/dc20-S006
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S73–S85. doi:10.2337/dc18-S008
   PubMed Web of Science ®Google Scholar
• Rhee SY, Kim HJ, Ko SH, et al. Monotherapy in patients with type 2 diabetes mellitus. Korean J Intern Med. 2017;32(6):959–966. doi:10.3904/kjim.2017.312
   Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98–S110. doi:10.2337/dc20-S009
   PubMed Web of Science ®Google Scholar
• Silver B, Ramaiya K, Andrew SB, et al. EADSG guidelines: insulin therapy in diabetes. Diabetes Ther. 2018;9(2):449–492. doi:10.1007/s13300-018-0384-6
   PubMed Web of Science ®Google Scholar
• Kalra S. Insulin Degludec aspart: the first co-formulation of insulin analogues. Diabetes Ther. 2014;5(1):65–72. doi:10.1007/s13300-014-0067-x
   PubMed Web of Science ®Google Scholar
• Pfohl M, Seufert J, Borck A, Bramlage P, Siegmund T. Effectiveness and safety of insulin glulisine when initiating supplementary prandial insulin treatment (SIT) in insulin-naïve patients with type 2 diabetes: the observational IGLU-SIT Study. Diabetes Ther. 2021;12(3):733–747. doi:10.1007/s13300-021-00998-z
   Web of Science ®Google Scholar
• Pfohl M, Siegmund T, Pscherer S, Pegelow K, Seufert J. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study. Vasc Health Risk Manag. 2015;11:569–578. doi:10.2147/VHRM.S82720
   PubMedGoogle Scholar
• Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamseh ME. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study. Diabetol Metab Syndr. 2013;5(1):57. doi:10.1186/1758-5996-5-57
   PubMed Web of Science ®Google Scholar
• Ketema EB, Kibret KT. Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systematic review and meta-analysis. Arch Public Health. 2015;73:43. doi:10.1186/s13690-015-0088-6
   PubMed Web of Science ®Google Scholar
• Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care. 1997;20(10):1539–1542. doi:10.2337/diacare.20.10.1539
   Web of Science ®Google Scholar
• Pampanelli S, Torlone E, Ialli C, et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care. 1995;18(11):1452–1459. doi:10.2337/diacare.18.11.1452
   Web of Science ®Google Scholar
• Giugliano D, Ceriello A, Razzoli E, Esposito K. Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus. Clin Drug Investig. 2008;28(4):199–210. doi:10.2165/00044011-200828040-00001
   PubMed Web of Science ®Google Scholar
• Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA; Orals Plus Apidra and LANTUS (OPAL) study group. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab. 2008;10(12):1178–1185. doi:10.1111/j.1463-1326.2008.00967.x
   Web of Science ®Google Scholar
• Meece J. Basal insulin intensification in patients with type 2 diabetes: a review. Diabetes Ther. 2018;9(3):877–890. doi:10.1007/s13300-018-0395-3
   Web of Science ®Google Scholar
• Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes–causes, effects and coping strategies. Diabetes Obes Metab. 2007;9(6):799–812. doi:10.1111/j.1463-1326.2006.00686.x
   PubMed Web of Science ®Google Scholar
• Karatoprak C, Yolbas S, Kiskac M, et al. The effects of short-acting analogue insulins on body weight in patients with type 2 diabetes mellitus. Turk J Med Sci. 2013;43(2):268–272.
   Web of Science ®Google Scholar